Search

Displaying results 3761 - 3770 of 4286 in total
  1. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...

  2. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was...

  3. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  4. Drug

    Mexazolam

    go.drugbank.com/drugs/DB15489
    Investigational

    [A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].

  5. Drug

    9MW3011

    go.drugbank.com/drugs/DB24999
    Investigational

    The drug is an anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibody.[L54591, L54596]

  6. Drug

    3-Acetylpyridine Adenine Dinucleotide

    go.drugbank.com/drugs/DB03363
    Experimental

    It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

  7. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.

  8. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).

  9. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  10. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.